All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @daniela.segura.shop on TikTok · 21s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @daniela.segura.shop's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Thanks for watching guys!

@daniela.segura.shop's semaglutide claims, fact-checked

Daniela.segura.shop

TikTok creator

48.2K viewsWatch on TikTok

Quick answer

Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying. The STEP 1 trial showed 14.9% average body weight reduction at 68 weeks with the 2.4mg dose. Treatment requires ongoing medical supervision due to potential gastrointestinal and metabolic side effects.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @daniela.segura.shop's semaglutide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@daniela.segura.shop's semaglutide claims, fact-checked" from Daniela.segura.shop. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying.

The reason this review is not generic is the source wording and the canonical claim label "glp1 mi verdadero cambio de este 2024 vamos 12 k." In this clip, the useful excerpt is: "Thanks for watching guys!" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Most dramatic weight loss occurs after month three, not during the initial 12 weeks
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Semaglutide is a GLP-1 receptor agonist that mimics incretin hormones to reduce appetite and slow gastric emptying. The STEP 1 trial showed 14.9% average body weight reduction at 68 weeks with the 2.4mg dose. Treatment requires ongoing medical supervision due to potential gastrointestinal and metabolic side effects.
  • Semaglutide at 2.4mg produces 14.9% average weight loss at 68 weeks according to the STEP 1 trial
  • Most dramatic weight loss occurs after month three, not during the initial 12 weeks

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide at 2.4mg produces 14.9% average weight loss at 68 weeks according to the STEP 1 trial
  • Most dramatic weight loss occurs after month three, not during the initial 12 weeks
  • Side effects affect 74% of users, with nausea being the most common at 44% incidence
  • Clinical trials included reduced-calorie diets and 150 minutes weekly exercise alongside medication
  • Treatment costs $1,300-1,500 monthly and most people regain weight when stopping
  • Weekly medical visits aren't standard protocol for stable semaglutide patients
  • Energy improvements likely result from weight loss rather than direct drug effects

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok creator actually claim?

Daniela Segura posted about losing 12 kilos (26 pounds) over three months using weekly semaglutide injections at MagicalMedSpa. She credits the GLP-1 medication with improving her energy levels and overall health beyond just weight loss.

The creator positions this as a supervised medical treatment rather than a quick fix. She's documenting ongoing weekly sessions and framing semaglutide as a "life-changing treatment."

While she doesn't specify her starting weight or dose, losing 26 pounds in 12 weeks works out to about 2.2 pounds per week. That's aggressive but potentially realistic for semaglutide users.

Does the science support these weight loss claims?

The numbers aren't outrageous for semaglutide. The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% average body weight reduction at 68 weeks with 2.4mg weekly doses. That study involved 1,961 adults without diabetes.

But here's the thing: most of semaglutide's dramatic weight loss happens after month three, not during it. The STEP trials showed average losses of 6-8% in the first 12 weeks.

If Daniela started at 140 pounds, losing 26 pounds represents an 18.6% reduction. That would put her in the top 10% of responders, which is possible but uncommon in early treatment.

What's missing from this success story?

The creator doesn't mention side effects, which hit about 74% of people in clinical trials. Nausea affects roughly 44% of users at the 2.4mg dose, according to the STEP 1 data.

She also skips the lifestyle component entirely. The STEP trials included reduced-calorie diets and 150 minutes of weekly exercise. Semaglutide alone, without dietary changes, produces much smaller weight losses.

Most concerning: she's getting treatment at a med spa, not from an endocrinologist or primary care doctor. While legal, this setup often lacks the comprehensive monitoring that GLP-1 medications require.

Are the energy claims legitimate?

This part gets tricky because energy improvements aren't directly measured in semaglutide trials. The STEP studies focused on weight, not subjective wellness measures.

However, the STEP 1 trial did show improvements in physical functioning scores on the SF-36 questionnaire. People reported better mobility and less physical limitation.

Weight loss itself often improves energy levels, so Daniela's experience could be real. But attributing it specifically to semaglutide rather than being 26 pounds lighter is misleading.

What should you actually know about semaglutide?

Semaglutide works by mimicking GLP-1, a hormone that slows stomach emptying and reduces appetite. The 2.4mg dose (Wegovy) is specifically approved for weight management, while lower doses (Ozempic) target diabetes.

The medication costs $1,300-1,500 monthly without insurance. Most people regain weight when they stop, according to the STEP 1 extension study.

Real medical supervision matters more than Daniela suggests. You need monitoring for pancreatitis, gallbladder problems, and potential thyroid issues. A legitimate provider will also address diet and exercise, not just hand you injections.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Daniela.segura.shop · TikTok creator

48.2K views on this video

😱😱😱 MI VERDADERO CAMBIO DE ESTE 2024!! 📣📣📣 Vamos 12 kilos menos!! (26 libras menos) Cambio de vida con el tratamiento de “Semaglutide” 💉☺️ Como cada semana tenemos sesión del tratamiento de

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide at 2.4mg produces 14.9% average weight loss at 68?

Semaglutide at 2.4mg produces 14.9% average weight loss at 68 weeks according to the STEP 1 trial

What does the video say about most dramatic weight loss occurs after month three, not during?

Most dramatic weight loss occurs after month three, not during the initial 12 weeks

What does the video say about side effects affect 74% of users, with nausea being the?

Side effects affect 74% of users, with nausea being the most common at 44% incidence

What does the video say about clinical trials included reduced-calorie diets?

Clinical trials included reduced-calorie diets and 150 minutes weekly exercise alongside medication

What does the video say about treatment costs $1,300-1,500 monthly?

Treatment costs $1,300-1,500 monthly and most people regain weight when stopping

What does the video say about weekly medical visits?

Weekly medical visits aren't standard protocol for stable semaglutide patients

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Daniela.segura.shop, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.